Tag Archives: Vorinostat

Adding vorinostat to bortezomib significantly improved progression-free survival.

Even though there have been excellent strides within the therapy of many myeloma over the past decade, most patients will eventually relapse or turn out to be resistant to remedy. What to do then can be a pressing clinical issue, … Continue reading

Posted in Uncategorized | Tagged | Leave a comment

Vorinostat will be the histone deacetylase (HDAC) inhibitor.

Soluble TRAIL and adenovirus (ad)-TRAIL exhibit a robust antitumor effect by inducing apoptosis. Vorinostat will be the histone deacetylase (HDAC) inhibitor that induces cell death in cancer cell lines and regulates the expression of epigenetically silenced genes, for example Coxackie … Continue reading

Posted in Uncategorized | Tagged | Leave a comment